Term of Royalty Obligations. The Royalty specified in Section 4.1 above shall continue for so long as Biovest manufactures, sales, commercializes, conducts a clinical trial, or licenses any Biovest Biologic Product.
Term of Royalty Obligations. The Royalties specified in Section 2.1 shall commence on the Effective Date, and shall continue, in each country on a product-by-product and country-by-country basis until the later of i) the date of expiration of the last to expire patent included within the Innovation, or ii) the date of expiration of the last strategic partnership/licensing agreement including the Innovation.
Term of Royalty Obligations. The royalty obligations specified in Section 4.2 above shall continue as to each Licensed Product in the Territory for the term of the last to expire of the Licensed Patent rights covering the Licensed Product.
Term of Royalty Obligations. GS’s obligation to make royalty payments pursuant to Section 10.3 shall commence as provided in Section 10.3 and shall continue until the later of: (i) the expiration of the last to expire of the LGLS Patents and GLAXO Patents claiming or covering such Product in such country, and (ii) 10 years after first commercial sale of such Product in such country. Following the expiration of GS’s royalty obligations, GS shall retain a non-exclusive, royalty-free right to use, sell and offer for sale Product in the Territory, using LGLS Know-how and GLAXO Know-how licensed to GS as of the Effective Date and the exclusive right to use the Trademarks for such purposes. GS shall continue to pay to LGLS a royalty in return for such right to use the Trademark, as provided in Section 11.4, below.
Term of Royalty Obligations. (a) Genentech shall pay royalties hereunder with respect to Franchise Products in each country in the Licensed Territory for eleven (11) years from the date of first commercial sale of such Franchise Product in such country.
Term of Royalty Obligations. OSCIENT’s obligation to make royalty payments pursuant to 10.3 shall commence as provided in Section 10.3 and shall continue until the later of: (i) the expiration of the last to expire of the LGLS Patents and GLAXO Patents claiming or covering such Product in such country, and (ii) 10 years after first commercial sale of such Product in such country; provided however, that, OSCIENT’s obligation to make royalty payments pursuant to 10.3 for Net Sales in Mexico and Canada shall continue until the later of: (I) the expiration of the last to expire of the LGLS Patents and GLAXO Patents claiming or covering such Product in Mexico or Canada, as the case may be, and (II) the period of data exclusivity in Mexico or Canada, as the case may be. Following the expiration of OSCIENT’s royalty obligations, OSCIENT shall retain a non-exclusive, royalty-free right to use, sell and offer for sale Product in the Territory, using LGLS Know-how and GLAXO Know-how licensed to OSCIENT as of the Effective Date and the exclusive right to use the Trademarks for such purposes. OSCIENT shall continue to pay LGLS a royalty in return for such right to use the Trademark, as provided in Section 11.4, below.
Term of Royalty Obligations. Roche’s obligation to pay royalties to PDL under Section 7.2(b)(i) with respect to any Excluded Product shall expire, on a country-by-country basis, on the later of (A) the last date on which the manufacture, use, sale, or importation in such country in the Roche Territory, by Roche, its Affiliates, or sublicensees (other than PDL, its Affiliates, and sublicensees) of such Excluded Product is covered under a Valid Claim of a PDL Patent (which determination, if not otherwise covered by a Valid Claim in the country of use, sale, or importation shall be based on whether or not covered by a Valid Claim in the country of manufacture), or (B) the [CONFIDENTIAL TREATMENT REQUESTED] of the first commercial sale by Roche, its Affiliates, or sublicensees (other than PDL, its Affiliates, or sublicensees) of such Excluded Product in such country.
Term of Royalty Obligations. [ * ]. ZENECA will notify ISIS promptly upon introduction of each Collaboration Product in each country. Upon termination of the royalty payment obligation, ZENECA will have, in perpetuity, a fully paid license under the ISIS Technology to discover, develop, make, have made, use, sell, have sold Collaboration Product without further accounting to ISIS. * CONFIDENTIAL TREATMENT REQUESTED
Term of Royalty Obligations. Subject to Sections 3.3(c) and 3.3(d) below, the royalty described in Section 3.3(a) shall be payable on Net Sales of a Product until the date upon which a generic equivalent of such Product, approved without authorization of Lilly, is launched in the United States; provided, however, that in the event that royalties are reduced pursuant to Section 3.3(d) in respect of a Product, royalties on such Product shall be payable until the date which is the earlier of(i) ten (10) years after the First Commercial Sale of the first Product and (ii) the date upon which a generic equivalent of such Product, approved without authorization of Lilly, is launched in the United States.
Term of Royalty Obligations. In the event that a Valid Claim of Improvement Patent Rights covering a Product exists in a particular country, the royalty described in Section 3.4(a) shall be payable for Net Sales of such Product in a country until the earlier of the date upon which such Valid Claim expires or is rendered invalid or deemed unpatentable to Sepracor in a judicial or administrative proceeding from which no appeal can be taken or the date upon which a generic equivalent of such Product, approved without authorization of Lilly, is launched.
